Biological
Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101 clinical trials
Also written PDS0101.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
3 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2020 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 3
M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · University of California, San Diego (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101 is read from its arms, and is right about nine times in ten.
Testing it · 3
- CASCADE: Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIVWithdrawnPhase 2University of California, San DiegoNCT07090174Written as PDS0101
- Combination Immunotherapy in Subjects With Advanced HPV Associated MalignanciesCompletedPhase 1/2National Cancer Institute (NCI)NCT04287868Written as PDS0101
- A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV TrialActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT04580771Written as Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101